207 related articles for article (PubMed ID: 33281109)
1. Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients.
Venderbos LDF; Deschamps A; Dowling J; Carl EG; Remmers S; van Poppel H; Roobol MJ
Eur Urol Focus; 2021 Sep; 7(5):987-994. PubMed ID: 33281109
[TBL] [Abstract][Full Text] [Related]
2. The Europa Uomo Patient Reported Outcome Study 2.0-Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making.
Venderbos LDF; Remmers S; Deschamps A; Dowling J; Carl EG; Pereira-Azevedo N; Roobol MJ
Eur Urol Focus; 2023 Nov; 9(6):1024-1036. PubMed ID: 37268512
[TBL] [Abstract][Full Text] [Related]
3. Sexual and urinary function in prostate cancer clinical studies and the Europa Uomo Patient Reported Outcome Study: does it match?
Remmers S; Venderbos LD; Deschamps A; Dowling J; Carl EG; Roobol MJ
Minerva Urol Nephrol; 2023 Apr; 75(2):188-193. PubMed ID: 36519924
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
[TBL] [Abstract][Full Text] [Related]
5. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
Ratti MM; Gandaglia G; Alleva E; Leardini L; Sisca ES; Derevianko A; Furnari F; Mazzoleni Ferracini S; Beyer K; Moss C; Pellegrino F; Sorce G; Barletta F; Scuderi S; Omar MI; MacLennan S; Williamson PR; Zong J; MacLennan SJ; Mottet N; Cornford P; Aiyegbusi OL; Van Hemelrijck M; N'Dow J; Briganti A;
Eur Urol Oncol; 2022 Apr; 5(2):153-163. PubMed ID: 34785188
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
Downing A; Wright P; Hounsome L; Selby P; Wilding S; Watson E; Wagland R; Kind P; Donnelly DW; Butcher H; Catto JWF; Cross W; Mason M; Sharp L; Weller D; Velikova G; McCaughan E; Mottram R; Allen M; Kearney T; McSorley O; Huws DW; Brewster DH; McNair E; Gavin A; Glaser AW
Lancet Oncol; 2019 Mar; 20(3):436-447. PubMed ID: 30713036
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors.
Spampinato S; Rancati T; Waskiewicz JM; Avuzzi B; Garibaldi E; Faiella A; Villa E; Magli A; Cante D; Girelli G; Gatti M; Noris Chiorda B; Rago L; Ferrari P; Piva C; Pavarini M; Valdagni R; Vavassori V; Munoz F; Sanguineti G; Di Muzio N; Kirchheiner K; Fiorino C; Cozzarini C
Acta Oncol; 2023 Nov; 62(11):1440-1450. PubMed ID: 37801288
[TBL] [Abstract][Full Text] [Related]
8. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
[TBL] [Abstract][Full Text] [Related]
10. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
11. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
12. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
14. Differences in Quality of Life between German and Dutch Patients with Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Implications for International Multicenter Randomized Controlled Trials.
Wagner C; Witt JH; Nolte S; van der Poel HG; Aaronson NK; Kolvatzis M; Tian Z; Mendrek M; Liakos N; Gratzke C; Leyh-Bannurah SR
Eur Urol Focus; 2023 Feb; ():. PubMed ID: 36863963
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
16. Establishing a population-based patient-reported outcomes study (PROMs) using national cancer registries across two jurisdictions: the Prostate Cancer Treatment, your experience (PiCTure) study.
Drummond FJ; Kinnear H; Donnelly C; O'Leary E; O'Brien K; Burns RM; Gavin A; Sharp L
BMJ Open; 2015 Apr; 5(4):e006851. PubMed ID: 25888474
[TBL] [Abstract][Full Text] [Related]
17. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy.
Lilleby W; Fosså SD; Waehre HR; Olsen DR
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):735-43. PubMed ID: 10098428
[TBL] [Abstract][Full Text] [Related]
18. Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; Coenen JLLM; van Moorselaar RJA; van den Berg P; Geenen MM; Mehra N; Hendriks MP; Lampe MI; van de Luijtgaarden ACM; Peters FPJ; Roeleveld TA; Smilde TJ; de Wit R; van Oort IM; Gerritsen WR; Uyl-de Groot CA
Clin Genitourin Cancer; 2020 Jun; 18(3):e233-e253. PubMed ID: 31883940
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment.
Bergius S; Torvinen S; Muhonen T; Roine RP; Sintonen H; Taari K
Scand J Urol; 2017 Feb; 51(1):13-19. PubMed ID: 27809631
[TBL] [Abstract][Full Text] [Related]
20. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
